BEDFORD, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that aPROMISE, its AIenabled FDA-cleared medical device software, is now available on the syngo.via platform, from Siemens Healthineers, one of the leading workstation systems. Siemens Healthineers will be demonstrating the integrated solution ...

Lantheus Holdings, Inc. (LNTH) has been gaining from its focus on pipeline development. The optimism, led by a solid first-quarter 2024 performance and strength in radiopharmaceuticals, is expected to contribute further. However, the company's dependence on third parties and macroeconomic concerns are major downsides. Over the past year, the Zacks Rank #2 (Buy) stock has lost 7.9% against the 2.9% growth of the industry. The S&P 500 has witnessed 26% growth in the said time frame. The renowned radiopharmace ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Lantheus Holdings (LNTH) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Lantheus Holdings is a member of our Medical group, which includes 1046 differ ...

BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the William Blair 44th Annual Growth Stock Conference at 2:40 p.m. CT on Tuesday, June 4. To access a live webcast of the presentation, please visit the Investors section of the Company's website at ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock. Lantheus Holdings (LNTH) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Research shows that stocks carrying the best growth features consistently beat the market. And for stocks th ...

Lantheus Holdings (LNTH) closed the last trading session at $78.22, gaining 19.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $102.63 indicates a 31.2% upside potential. The average comprises eight short-term price targets ranging from a low of $96 to a high of $110, with a standard deviation of $5.32. While the lowest estimate indicates an increase of 22.7% from the current pr ...

It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days. Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the s ...

Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer BEDFORD, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Jeffrey S. Humphrey, MD has been appointed Chief Medical Officer (CMO) and Jean-Claude Provost, MD has been named Chief Science Officer ...

Lantheus Holdings (LNTH) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this diagnostic imaging company have returned +26.4%, compared to the Zacks S&P 500 composite's -0.4% change. During this period, the Zacks Medical - Products industry, which Lantheus Holdings falls in, has lost 1.5%. The key question now is: What could be the stock's future d ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Mark Kinarney - Vice President of Investor Relations Brian Markison - Chief Executive Officer Paul Blanchfield - President Bob Marshall - Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Financial Group Roanna Ruiz - Leerink Partners LLC Richard Newitter - Truist Securities Larry Solow - CJS Securities Yuan Zhi - B. Riley Justin Walsh - Jones Trading Andy Hsieh - Wi ...